News

Bal Pharma Limited announced that it has disbursed a final dividend of Rs 1.20 per equity share of Rs 10 each for the financial year 2025–26, following approval at its 39th Annual General Meeting on September 24, 2026. The company withheld dividend payments for shareholders with incomplete KYC details or invalid bank accounts, and those amounts will be transferred to the Company’s Unpaid Dividend Account after 30 days, in accordance with the Companies Act, 2013. Shareholders are advised to update their KYC and bank account details with MUFG Intime India Private Limited, the company’s Registrar and Transfer Agent, to facilitate the release of withheld dividends.

Bal Pharma Limited informed the National Stock Exchange of India Limited and BSE Limited that, based on a certificate received from its Registrar and Transfer Agent, MUFG Intime India Private Limited, the details of securities dematerialised/rematerialised during the quarter ended September 30, 2026, have been duly furnished to both stock exchanges within the prescribed time limit.

Bal Pharma Limited announced that its members approved the re-appointment of Ravindra Kumar Kothari as a director liable to retire by rotation and a change in his designation from Non-Executive Director to Whole-Time Director, designated as Executive Director, effective October 1, 2026. Additionally, Virupakshaya Himesh’s designation changed from Whole-Time Director to Non-Executive Director, also effective October 1, 2026, resulting in the reconstitution of the Nomination and Remuneration Committee and the Stakeholders’ Relationship Committee.

Bal Pharma Limited will close its trading window from October 1, 2026, until 48 hours after the announcement of its financial results for the second quarter ending September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Bal Pharma Ltd. announced the allotment of 10,00,000 warrants on a preferential basis to promoter Mr. Shailesh Siroya, for Rs 8,40,00,000, at an issue price of Rs 84 per warrant. The company received Rs 2,10,00,000, representing 25% of the total amount payable for the warrants, and the allotment was approved by the board on September 7, 2026. Each warrant is convertible into one equity share with a face value of Rs 10 and a premium of Rs 74, and can be exercised within 18 months from the allotment date.